Analgesic Efficacy of Maxigesic in Breast Cancer Surgery

Recruiting now · Not applicable

Conditions studied: Breast Cancer

In brief

The present study aims to find a perioperative analgesic method that provides sufficient analgesia while reducing immune compromise in cancer surgery. This study is to investigate the analgesic effect and safety of Maxigesic inj. (a combination of acetaminophen 1000 mg and ibuprofen 300 mg), which is added to opioid-based IV-PCA in patients undergoing breast cancer surgery.

Key facts

Study ID

NCT06174363

Run by

Yonsei University

People needed

84

Starts

2023-12-28

Expected to finish

2025-12-26

Last updated by the study team

2025-07-20

Who can join

Age: 20 and older, up to 70. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patient aged 20 to 70 years with ASA classification 1 to 3 undergoing breast cancer surgery (cancer resection or reconstruction)

You may not qualify if…

• ASA classification 4/ allergy to acetaminophen, NSAIDs, opioid/ severe liver or renal dysfunction/ pregnancy

Where it is running

• Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.